Radionetics Oncology
Istvan Molnar is currently serving as the Chief Medical Officer at Radionetics Oncology. Prior to this, Istvan held various leadership roles in companies such as KGIM Enterprises LLC, Lantheus Medical Imaging, Fusion Pharmaceuticals, Merrimack Pharmaceuticals, and Bayer HealthCare. Istvan is a highly experienced medical professional with a background in hematology, oncology, and internal medicine. Istvan's expertise includes clinical development, global medical affairs, and leading cross-functional teams. Istvan completed a Doctor of Medicine degree from Semmelweis University and has a board certification in Hematology, Oncology, and Internal Medicine. Throughout Istvan's career, he has demonstrated strong leadership skills and a commitment to medical excellence.
Radionetics Oncology
Radionetics Oncology is a pharmaceutical company focused on the discovery and development of novel radiotherapeutics for the treatment of a wide range of oncology indications. The company’s platform technology uses nonpeptide, small molecule targeting to deliver therapeutic radioisotopes to a broad range of cancers by binding selectively to peptide receptors that are selectively expressed on these tumors. This nonpeptide technology addresses many of the significant challenges currently facing peptide and protein targeted radiotherapeutics, particularly in the realm of optimizing drug-like characteristics and manufacturing. The company is rapidly advancing a pipeline of drug candidates to treat a broad range of cancers and is conducting additional drug discovery efforts to identify drug candidates for additional receptor targets in collaboration with Crinetics Pharmaceuticals.